Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04637009
Recruitment Status : Recruiting
First Posted : November 19, 2020
Last Update Posted : August 31, 2021
Sponsor:
Information provided by (Responsible Party):
Astex Pharmaceuticals, Inc.

Brief Summary:

This is a Phase 1, 2-part, open-label, multicenter, first-in-human (FIH) study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of TAS1553 administered orally to participants ≥18 years of age with relapsed or refractory (R/R) acute myeloid leukemia (AML) or other myeloid neoplasms where approved therapies have failed or for whom known life-prolonging therapies are not available. The AML population includes de novo AML, secondary AML, and myelodysplastic syndrome (MDS)-transformed into AML. Other myeloid neoplasms include accelerated phase myeloproliferative neoplasms (MPN), and chronic or accelerated phase MPN-unclassifiable (MPN-U) and MDS-MPN. Blast crisis phase of MPNs are considered secondary AML and will be included in the AML cohort.

Part 1 is a multicenter, sequential group treatment feasibility study with 1 treatment arm and no masking (dose escalation). Part 2 is a multicenter, two-stage, multiple group, dose confirmation study with 1 treatment arm and no masking (exploratory dose expansion).


Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Myeloproliferative Neoplasm Myelodysplastic/Myeloproliferative Neoplasm Drug: TAS1553 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Actual Study Start Date : December 21, 2020
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : August 31, 2023


Arm Intervention/treatment
Experimental: Part 1 (dose escalation)
Oral administration of TAS1553 once daily at specific time points.
Drug: TAS1553
Form: tablet; Route of Administration: oral

Experimental: Part 2 (dose expansion)
Oral administration of TAS1553 once daily at specific time points.
Drug: TAS1553
Form: tablet; Route of Administration: oral




Primary Outcome Measures :
  1. Safety: Number of participants with treatment-emergent adverse events in Part 1 [ Time Frame: Up to 12 months ]
  2. Safety: Number of participants with dose-limiting toxicities in Part 1 [ Time Frame: Up to 12 months ]
  3. Response rate in Cohort 1 (AML): Number of participants with complete response (CR) + complete response with partial hematological recovery (CRh), and with CR + incomplete blood count recovery (CRi) in Part 2 [ Time Frame: Up to 33 months ]
  4. Response rate in Cohort 2 (other myeloid neoplasms): Number of participants with overall response rate (ORR) of CR + partial response (PR) in Part 2 [ Time Frame: Up to 33 months ]

Secondary Outcome Measures :
  1. Pharmacokinetic parameter: Area under the curve (AUC) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
  2. Pharmacokinetic parameter: Maximum plasma concentration (Cmax) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
  3. Pharmacokinetic parameter: Minimum plasma concentration (Cmin) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
  4. Pharmacokinetic parameter: Time to reach maximum plasma concentration (Tmax) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
  5. Pharmacokinetic parameter: Half-life (t½) [ Time Frame: At specific timepoints from predose up to Day 8 of Cycle 6 (28 days per cycle) ]
  6. Hematological improvement: Number of participants in Cohort 2 (other myeloid neoplasms) with hematological improvement in Part 2 [ Time Frame: Up to 33 months ]
  7. Time to response (TTR): Number of days from the first dose to the first documented evidence of response [ Time Frame: Up to 33 months ]
  8. Duration of response (DOR): Number of days from the start of response until disease progression or relapse [ Time Frame: Up to 33 months ]
  9. Overall survival (OS): Number of days from date of first dose until death due to any cause [ Time Frame: Up to 33 months ]
  10. Safety: Number of participants with treatment-emergent adverse events in Part 2 [ Time Frame: Up to 33 months ]
  11. Pharmacodynamic biomarker: Change from baseline in deoxyadenosine triphosphate (dATP) pool levels in peripheral blood mononuclear cells (PBMCs) [ Time Frame: At specific timepoints from predose up to Day 2 of Cycle 2 (28 days per cycle) ]
  12. Pharmacodynamic biomarker: Change from baseline in phosphorylated checkpoint kinase 1 (pCHK1) levels in bone marrow [ Time Frame: At specific timepoints from predose up to Day 2 of Cycle 2 (28 days per cycle) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capable of giving signed informed consent.
  2. Participant must be 18 years of age or older, at the time of signing the informed consent.
  3. Life expectancy of at least 12 weeks as assessed by the investigator.
  4. Participants with R/R AML or other myeloid neoplasms where approved therapies have failed or for whom known life-prolonging therapies are not available. The AML population includes de novo AML, secondary AML, and MDS transformed into AML. Other myeloid neoplasms include accelerated phase MPN, and chronic or accelerated phase MPN-U and MDS-MPN. Blast crisis phase of MPN, MPN-U, and MDS-MPN are considered secondary AML and will be included in the AML cohort.
  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  6. Have platelet count ≥10,000/μL (transfusions to achieve this level are allowed).
  7. Have adequate renal function as demonstrated by a 24-hour urine measured creatinine clearance ≥60 mL/min.
  8. Adequate hepatic function as evidenced by:

    1. aspartate aminotransferase (AST) ≤3× upper limit of normal (ULN)
    2. alanine aminotransferase (ALT) ≤3×ULN
    3. total bilirubin ≤1.5×ULN.
  9. Participants must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study.
  10. Women of child-bearing potential (according to recommendations of the Clinical Trial Facilitation Group [CTFG]) must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.

Exclusion Criteria:

  1. Participants who have MPN, MPN-U, or MDS/MPN and display hypoplastic bone marrow and would also not ordinarily benefit from cytoreductive therapy such as hydroxyurea (HU).
  2. Participants with highly proliferative disease are excluded as follows:

    1. Part 1/AML: white blood cells (WBC) >20,000/μL and >50% blasts in blood. Measures to reduce WBC, such as HU treatment within the last 2 weeks and cytotoxic chemotherapy within the last 4 weeks are not allowed to meet this eligibility criterion.
    2. Part 1/other myeloid neoplasms: WBC >20,000/μL. A short course of HU may be used to meet this eligibility criterion, as long as HU is discontinued 96 hours and any encountered drug-related toxicity must be resolved to Grade ≤1 before the first dose of study treatment.
    3. Part 2/Cohort 1, AML: WBC>20,000/μL and >50% blasts in blood. A short course of HU may be used to meet this eligibility criterion, as long as HU is discontinued 96 hours, and any encountered drug-related toxicity must be resolved to Grade ≤1 before the first dose of study treatment.
    4. Part 2/Cohort 2, other myeloid neoplasms: Specific WBC exclusion criterion not defined. A short course of HU may be used to reduce WBC if judged to be necessary by the investigator, as long as HU is discontinued 96 hours and any encountered drug-related toxicity must be resolved to Grade ≤1 before the first dose of study treatment.
  3. Known clinically active central nervous system (CNS) leukemia.
  4. Diagnosis of BCR-ABL-positive leukemia, acute promyelocytic leukemia (M3 AML or APML), or juvenile myelomonocytic leukemia (JMML).
  5. Second malignancy requiring active systemic therapy, except breast or prostate cancer stable on or responding to endocrine therapy.
  6. Ongoing Grade ≥3 Graft Versus Host Disease (GVHD), or any grade GVHD requiring active treatment (for example, calcineurin inhibitors, ≥5mg/day prednisone or other steroid equivalent, or other immunosuppressive agents). (Note: Prednisone at any dose for other indications is allowed).
  7. Advanced human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; Inactive hepatitis carrier status and participants with laboratory evidence of no active replication and participants on antiviral medication(s) who have a viral load below limit of detection will be permitted.
  8. Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of non-compliance with the protocol.
  9. Active infection resistant to antibiotics; or non-leukemia-associated pulmonary disease requiring >2 liters per minute oxygen or any other condition that puts the participant at an imminent risk of death.
  10. 24-hour urinary protein excretion ≥1g or urinalysis of 2+proteinuria.
  11. History of, or at risk for, cardiac disease, as evidenced by any of the following conditions:

    1. Abnormal left ventricular ejection fraction (LVEF; <50%) on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan at Screening.
    2. Congestive cardiac failure of Class ≥III severity according to New York Heart Association (NYHA) functional classification defined as patients with marked limitation of activity and who are comfortable at rest, while Class IV patients have symptoms of heart failure at rest.
    3. Unstable cardiac disease including unstable angina or hypertension as defined by the need for overnight hospital admission within the last 3 months (90 days).
    4. Ventricular arrhythmias including ventricular bigeminy, clinically significant brady arrhythmias such as sick sinus syndrome, third-degree atrioventricular (AV) block, presence of cardiac pacemaker or defibrillator, or other clinically significant arrhythmias.
    5. Screening 12-lead electrocardiogram (ECG) with measurable QTcF interval of ≥470 msec (Fridericia's formula should be used).
  12. Known hypersensitivity to TAS1553 or any of its components.
  13. Allogenic hematopoietic stem cell transplantation (HSCT) within 180 days of the first dose of TAS1553, or participants on immunosuppressive therapy post HSCT at the time of screening (calcineurin inhibitors or similar must be discontinued ≥4 weeks prior to the time of study drug initiation).
  14. Treated with any systemic anticancer therapy within 2 weeks of the first dose of study treatment. Any encountered treatment-related toxicities (excepting alopecia) must be resolved to Grade 1 or less.
  15. Phase 1 Part 1 only: participants who require concomitant use of strong CYP3A4 inducers.
  16. Inability to swallow oral medication.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04637009


Contacts
Layout table for location contacts
Contact: General Inquiries 9255600100 info@astx.com

Locations
Layout table for location information
United States, Alabama
University of Alabama - Birmingham Comprehensive Cancer Center Recruiting
Birmingham, Alabama, United States, 35233
Contact: Tonya Cole    205-975-7162    tdcole@uabmc.edu   
Principal Investigator: Pankit Vachhani, MD         
United States, Arizona
HonorHealth Research Institute Recruiting
Scottsdale, Arizona, United States, 82528
Contact: Nyssa Hoffman    480-946-4455    Nyssa.Hoffman@HonorHealth.com   
Contact: Christine Canilao    480-323-1323    ccanilao@honorhealth.com   
Principal Investigator: Veena Fauble, MD         
Sub-Investigator: Christina Pierce, MD         
Sub-Investigator: Kathryn Steenstra, MD         
United States, California
University of Southern California Keck School of Medicine Recruiting
Los Angeles, California, United States, 90033
Contact: Christine Duran    323-865-0089    duran_c@med.usc.edu   
Principal Investigator: Casey O'Connell, MD         
United States, Georgia
Augusta University - Georgia Cancer Center Recruiting
Augusta, Georgia, United States, 30912
Contact: Kelly Jenkins    706-721-1206      
Principal Investigator: Jorge Cortes, M.D         
United States, Kentucky
Norton Cancer Institute Recruiting
Louisville, Kentucky, United States, 40241
Contact: Heather Woolridge    502-899-3366 ext 19211    heather.woolridge@nortonhealthcare.org   
Contact: Joshua Roberts    502-899-3386 ext 19291    joshua.roberts@nortonhealthcare.org   
Principal Investigator: Joseph Maly, MD         
Sub-Investigator: Don Stevens, MD         
Sub-Investigator: Sandy Stencavage, MD         
Sub-Investigator: Amy McCaa, MD         
Sub-Investigator: Dana Haycraft, MD         
Sub-Investigator: Dale Vincent, MD         
United States, New York
Weill Cornell Medicine and New York - Presbyterian Hospital Recruiting
New York, New York, United States, 10065
Contact: Alekya Kaveli    347-233-9068      
Principal Investigator: Gail Roboz, M.D         
United States, Ohio
Cleveland Clinic Taussig Cancer Institute Recruiting
Cleveland, Ohio, United States, 44195
Contact: Brielle Brath         
Principal Investigator: Sudipto Mukherjee         
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Vicky Zoeller    713-745-8461    vhzoelle@mdanderson.org   
Principal Investigator: Yesid Alvarado-Valero, MD         
Sub-Investigator: Allison Pike         
Canada, Alberta
University of Alberta Hospital - Hematology Research Recruiting
Edmonton, Alberta, Canada, T6G 2V2
Contact: Michelle Chu    780-266-7337      
Principal Investigator: Joseph Brandwein         
Canada, Ontario
Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2L7
Contact: Karen Yee, MD    416-946-4501 ext 7808    Karen.Yee@uhn.ca   
Principal Investigator: Karen Yee, MD         
Sponsors and Collaborators
Astex Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Jason Taylor, MD PhD Astex Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Astex Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04637009    
Other Study ID Numbers: TAS1553-01
First Posted: November 19, 2020    Key Record Dates
Last Update Posted: August 31, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Astex Pharmaceuticals, Inc.:
MDS/MPN, unclassifiable in chronic phase
Accelerated phase MPN
Chronic neutrophilic leukemia (CNL), accelerated phase
Polycythemia vera (PV), accelerated phase
Primary myelofibrosis (PMF), accelerated phase
Essential thrombocythemia (ET), accelerated phase
Chronic eosinophilic leukemia, not otherwise specified (NOS), accelerated phase
MPN, unclassifiable
MDS/MPN
Chronic myelomonocytic leukemia (CMML)
Atypical chronic myeloid leukemia (aCML), BCR-ABL1-negative
MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
MDS/MPN, unclassifiable
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Neoplasms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases